Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Daveigh Elizabeth Chase ( də-VAY; née Chase-Schwallier; July 24, 1990 – June 16, 2026) was an American actress. Chase began her acting career as a child, portraying Samantha Darko in the psychological thriller film Donnie Darko (2001) and Samara Morgan in the American remake of the horror film The Ring (2002). She also provided the English dub voice of Chihiro Ogino in the Studio Ghibli film Spirited Away (2001) and voiced Lilo Pelekai in the Disney animated film Lilo & Stitch (2002) and its related media franchise. She later took on adult roles, including in the HBO drama series Big Love (2006–2011) and independent films such as Yellow (2012) and Jack Goes Home (2016). Chase received three awards from six nominations, including an Annie Award for Outstanding Achievement for Voice Acting and an MTV Movie Award for Best Villain. Chase retired from acting in 2016 and later died on June 16, 2026 from complications associated with AIDS.
=== Synthetic polymers === ECD studies of polyalkene glycols, polyamides, polyacrylates and polyesters are useful for understanding composition of polymer samples. It has become a powerful technique to analyze structural information about precursor ions during MS/MS for synthetic polymers. ECD's single bond cleavage tendency makes the interpretation of product ion scans simple and easy for polymer chemistry.
== History == 2000: Four scientists from what was then the Agricultural University of Norway (NLH), now the Norwegian University of Life Sciences (UMB) had the idea of replacing traditional date-stamping with something that can give a more correct indication of remaining shelf life for temperature sensitive products, such as food and pharmaceuticals. 2001: The fundamental principles for a shelf-life indicator were verified in the laboratory. The company TimeTemp AS, now Keep-it Technologies, was founded in 2001 to develop the technology into a commercial product. 2003: TimeTemp comes in second place in DNB’s national innovation competition. 2003-2007: The technology is tested and developed in the university's laboratories, and a working laboratory prototype is created. Keep-it Technologies is granted a patent in a number of different countries, including the US, Canada, Australia and New Zealand. 2007-2009: With support from the Research Council of Norway, Keep-it Technologies initiates an R&D project to develop the technology from laboratory prototype to an industrial prototype, and test it on real products through a professional cold chain. 2010-2011: The company raises new investment capital and initiates an IFU project that develops the first consumer version of the indicator. The indicator is tested on the first products in the Norwegian grocery market. 2012: Keep-it indicator is commercialized in Norway with the Norwegian retailer, Rema 1000. 2018: Keep-it has indicators on 30 different fresh products at Rema 1000, Kolonial.no and Oslo University Hospital.
Sources: en.wikipedia.org
== History == According to traditional methods, most organic compounds are synthesized one by one from building blocks coupling them together one after the other in a stepwise manner. Before 1982 nobody was even dreaming about making hundreds or thousands of compounds in a single process. Not speaking about millions or even trillions. So the productivity of the split and pool method invented by Prof. Á. Furka (Eötvös Loránd University Budapest Hungary), in 1982 seemed incredible at first sight. The method had been described it in a document notarized in the same year. The document is written in Hungarian and translated to English Motivations that led to the invention are found in a 2002 paper and the method was first published in international congresses in 1988 then in print in 1991.
== Mechanical characteristics == While many uses of ivory are purely ornamental in nature, it often must be carved and manipulated into different shapes to achieve the desired form. Other applications, such as ivory piano keys, introduce repeated wear and surface handling of the material. It is therefore essential to consider the mechanical properties of ivory when designing alternatives. Elephant tusks are the animal's incisors, so the composition of ivory is unsurprisingly similar to that of teeth in several other mammals. It is composed of dentine, a biomineral composite constructed from collagen fibers mineralized with hydroxyapatite. This composite lends ivory the impressive mechanical properties—high stiffness, strength, hardness, and toughness—required for its use in the animal's day-to-day activities. Ivory has a measured hardness of 35 on the Vickers scale, exceeding that of bone. It also has a flexural modulus of 14 GPa, a flexural strength of 378 MPa a fracture toughness of 2.05 MPam1/2. These measured values indicate that ivory mechanically outperforms most of its most common alternatives, including celluloid plastic and polyethylene terephthalate. Ivory's mechanical properties result from the microstructure of the dentine tissue. It is thought that the structural arrangement of mineralized collagen fibers could contribute to the checkerboard-like Schreger pattern observed in polished ivory samples. This is often used as an attribute in ivory identification.
=== Effects of drugs on propranolol === Propranolol is metabolized by cytochrome P450 enzymes including CYP2D6, CYP1A2, and CYP2C19. Levels of propranolol may be increased by CYP2D6 inhibitors such as amiodarone, bupropion, cimetidine, duloxetine, fluoxetine, paroxetine, propafenone, quinidine, and ritonavir, by CYP1A2 inhibitors such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, theophylline, zileuton, zolmitriptan, and rizatriptan, and by CYP2C19 inhibitors such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide. No interactions with propranolol were observed with ranitidine, lansoprazole, or omeprazole. Propranolol levels may be reduced by inducers of hepatic metabolism including rifampin, alcohol, phenytoin, phenobarbital, and cigarette smoking. The CYP2D6 inhibitor quinidine has been found to increase propranolol levels by 2- to 3-fold. The CYP1A2 inhibitor fluvoxamine has been found to increase propranolol levels by 5-fold. The calcium channel blocker nisoldipine increased peak levels of propranolol by 1.5-fold and area-under-the-curve levels by 1.3-fold, while nicardipine increased propranolol peak levels by 1.8-fold and area-under-the-curve levels by 1.5-fold. Conversely, verapamil does not affect the pharmacokinetics of propranolol and vice-versa. The CYP1A2 inhibitor zolmitriptan increased peak propranolol levels by 1.4-fold and area-under-the-curve levels by 1.56-fold, while the CYP1A2 inhibitor rizatriptan increased propranolol peak levels by 1.8-fold and area-under-the-curve levels by 1.7-fold.
Sources: en.wikipedia.org
Plantar fasciitis or plantar heel pain is a disorder of the plantar fascia, which is the connective tissue that supports the arch of the foot. It results in pain in the heel and bottom of the foot that is usually most severe with the first steps of the day or following a period of rest. Pain is also frequently brought on by bending the foot and toes up towards the shin. The pain typically comes on gradually. It affects both feet in about one-third of cases. The cause of plantar fasciitis is not clear. Risk factors include overuse, such as from long periods of standing, an increase in exercise, and obesity. It is associated with inward rolling of the foot, a tight calf muscle and Achilles tendon, and a sedentary lifestyle. Heel spurs may play a role; they are commonly present in people who have the condition. Plantar fasciitis is a disorder of the insertion site of the ligament on the bone characterized by micro tears, collagen breakdown, and scarring. Inflammation plays either a lesser or no role. A review proposed that the disorder be renamed plantar fasciosis. Presentation of symptoms is generally the basis for diagnosis. Conditions with similar symptoms include osteoarthritis, ankylosing spondylitis, heel pad syndrome, and reactive arthritis. Ultrasound can be useful in cases where the symptoms do not imply a diagnosis. Most cases resolve with time and conservative treatment. For the first few weeks, treatment involves rest, reduced activities, pain medications, and stretching. The next level involves physiotherapy, orthotics, splinting, or steroid injections.
Synephrine, or, more specifically, p-synephrine, is an alkaloid, occurring naturally in some plants and animals, and also in approved drugs products as its m-substituted analog known as neo-synephrine. p-Synephrine (or formerly Sympatol and oxedrine [BAN]) and m-synephrine are known for their longer acting adrenergic effects compared to epinephrine and norepinephrine. This substance is present at very low concentrations in common foodstuffs such as orange juice and other orange (Citrus species) products, both of the "sweet" and "bitter" variety. The preparations used in traditional Chinese medicine (TCM), also known as Zhi Shi (枳实), are the immature and dried whole oranges from Citrus aurantium (Fructus Aurantii Immaturus). Extracts of the same material or purified synephrine are also marketed in the US, sometimes in combination with caffeine, as a weight-loss-promoting dietary supplement for oral consumption. While the traditional preparations have been in use for millennia as a component of TCM-formulas, synephrine itself is not an approved over the counter drug. As a pharmaceutical, m-synephrine (phenylephrine) is still used as a sympathomimetic (i.e. for its hypertensive and vasoconstrictor properties), mostly by injection for the treatment of emergencies such as shock, and rarely orally for the treatment of bronchial problems associated with asthma and hay-fever.
These mutations may enable the mutant organism to withstand particular environmental stresses better than wild type organisms, or reproduce more quickly. In these cases a mutation will tend to become more common in a population through natural selection. Viruses that use RNA as their genetic material have rapid mutation rates, which can be an advantage, since these viruses thereby evolve rapidly, and thus evade the immune system defensive responses. In large populations of asexually reproducing organisms, for example, E. coli, multiple beneficial mutations may co-occur. This phenomenon is called clonal interference and causes competition among the mutations.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.